Immunotherapy grants

Main applicant must be an established investigator with primary employment at a university, hospital, or non-profit research institution in a Nordic country (Denmark, Sweden, Norway, Finland, Iceland, Greenland, Faroe Islands). Translational/applied focus on regenerative medicine (stem cell-based therapies); fundamental discovery, adult immune cell (CAR-T/NK), and gene therapy projects are out of scope. For-profit partners may collaborate but cannot receive direct funding (subcontractors excepted).

Supports postdoctoral researchers in immunology and cancer immunology at non-profit institutions worldwide (no citizenship restrictions). Applicants must hold a doctoral degree by award activation and have <5 years of mentored research experience (M.D.s exclude residency years). Research must be hypothesis-driven and mechanistic, relevant to the immune system's role in cancer. Only 1 fellow per sponsor per round.

For postdoctoral researchers with <5 years mentored research experience at award activation, working at the intersection of cancer immunology and computational biology/data science. Must be conducted at a non-profit institution (US or abroad); no citizenship restrictions. Sponsor must hold assistant professor or higher rank. Proposals must be hypothesis-driven in basic or translational cancer immunology.

Supports outstanding early-career postdoctoral scientists seeking dual expertise in immunology and data science at the intersection of cancer immunology and bioinformatics/computational methods.

Main applicant must be an established investigator with primary employment at a university, hospital, or non-profit research institution in a Nordic country (Denmark, Sweden, Norway, Finland, Iceland, Greenland, Faroe Islands). Translational/applied focus on stem cell-based therapies across four themes: allogeneic cell therapy, analytical methods, biomaterials, and clinical development. Fundamental discovery, adult immune cell (CAR-T/NK), and gene therapy projects are out of scope.

Supports early-stage, pre-development technological innovations in cancer immunotherapy (computational, profiling, visualization, culture systems, novel therapeutics). Applicants must hold a tenure-track position at a not-for-profit research institution. Co-PIs encouraged. Does not fund clinical trials or continuation of existing technologies. Proposals must be submitted in English.

Supports early-stage, pre-development concepts with potential to transform cancer immunotherapy. Targets bold, innovative technology ideas at the pre-development stage in cancer immunotherapy.

Funds investigator-initiated phase I/II or phase II immunotherapy clinical trials led by academic PIs. Open to researchers at medical schools or research centers in the US or abroad; no citizenship restrictions; for-profit institutions ineligible. Emphasis on novel immunotherapy, mechanistic insights, and biomarker discovery. Up to 10% indirect costs provided in addition to award. Co-funding available for chordoma-focused proposals (with Chordoma Foundation).

Supports innovative investigations at the intersection of laboratory discovery and clinical application in cancer immunology, accelerating translation of immunological discoveries into cancer therapies. Requires integration of clinical and laboratory components.

Supports pioneering immunotherapy clinical trials designed and led by academic researchers. Requires a clinical trial focus; applicants must be academic investigators leading immunotherapy trials.

Open to tenure-track assistant professors or higher at non-profit medical schools and research centers worldwide (US or abroad); no citizenship restrictions. Funds translational cancer immunology research bridging lab discovery and clinical application. For-profit institutions are ineligible. A chordoma-focused sub-track is co-funded with the Chordoma Foundation.

Supports the transition of distinguished postdoctoral researchers into independent tenure-track investigators in cancer immunotherapy. Aimed at researchers at the postdoc-to-faculty transition stage.

For mid-career scientists (tenure-track assistant professors with ≥3 years or associate professors with ≤3 years in role) with MD, PhD, or MD/PhD. Minimum 80% time commitment to research. Open globally; host institution must be a non-profit medical school or research center (US or abroad). For-profit institutions ineligible. Adjunct/acting positions not eligible. Funds high-risk, high-reward cancer immunotherapy research.

Supports mid-career scientists pursuing high-risk, high-reward research at the leading edge of cancer immunotherapy. Targets established investigators with bold, transformative research directions.

Lead applicant must be based at a not-for-profit organisation in the UK, Republic of Ireland, or a low/middle-income country (excl. India and mainland China). Teams of 3–5 applicants required; coapplicants can be worldwide except mainland China. Supports novel bioimaging technology development at cell-tissue scale. Lead must contribute ≥20% research time and hold a permanent/open-ended contract. UK/Ireland leads cannot claim salary.

Funds human-centric mechanistic experimental medicine studies testing hypotheses about disease mechanisms using interventions (compounds, biologics, psychological, physiological, vaccines, immune challenges). Requires human participant recruitment with clinical infrastructure. New Investigator Award track available. Applications in English; UK institutions. No matched funding requirement beyond standard 20% FEC.

Pilot data generation and hypothesis-driven mechanistic studies examining inflammatory and immune processes in neurological conditions and mental illness. Excludes GWAS/epidemiological studies and MS-only projects. Funded at 80% full economic cost; PhD studentship costs not eligible. UK institutions; principal investigator CV and key publications required at expression of interest stage.

Pilot grant addressing an emerging gap in support for new clinical trials in DIPG. Funds hiring of a clinical fellow to support clinical trial work (e.g., CAR-T cell trials). First-time award; check the grant application page for future availability.